Estrogen-progestagen therapy in the management of the polycystic ovary syndrome

Journal of Endocrinological Investigation

Volumn 21, Issue 9, 1998, Pages 618-622

  Marshall, J C ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Estrogens; Polycystic ovary syndrome; Progestagens

Indexed keywords

ESTROGEN; HORMONE; LUTEINIZING HORMONE; PROGESTERONE;

ARTICLE; FEMALE; HIRSUTISM; HUMAN; HYPERANDROGENISM; LUTEINIZING HORMONE RELEASE; OVARY FUNCTION; OVARY POLYCYSTIC DISEASE;

EID: 0031782011     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03350787     Document Type: Article

References (31)

1. Ehrmann D.A., Barnes R.B., Rosenfeld R.L. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocr. Rev. 16: 322, 1995.
2. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanisms and implications for pathogenesis. Endocr. Rev. 18: 774, 1997.
3. Waldstreicher J., Santoro N.F., Hall J.E., Filicori M., Crowley W.F. Hyperfunction of the hypothalamic-pituitary axis in women with PCO. J. Clin. Endocrinol. Metab. 66: 165, 1988.
4. Berga S.L., Guzick D.S., Winters S.J. Increased LH and α subunit secretion in women with hyperandrogenemic anovulation. J. Clin. Endocrinol. Metab. 77: 895, 1993.
5. Chang R.J., Laufer L.R., Meldrum D.R., Judd H.L Steroid secretion in polycystic ovarian disease after ovarian suppression by a long-acting gonadotropin-releasing hormone agonist. J. Clin. Endocrinol. Metab. 56: 897, 1983.
6. Yen S.S.C., Chaney C., Judd H.L. Functional aberrations of the hypothalamic-pituitary system in PCOS- a consideration of pathogenesis. In: The Endocrine Function of the Human Ovary, Academic Press N.Y., 1976, p. 373.
7. Chang R.J., Manfdel F.P., Lu J.K., Judd H.L. Enhanced disparity of gonadotropin secretion by estrone in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 54: 490, 1982.
8. Dunaif A., Longcope C., Canick J., Badger T., Crowley W.F. The effects of the aromatase inhibitor delta 1 - testolactone on gonadotropin release and steroid metabolism in polycystic ovary disease. J. Clin. Endocrinol. Metab. 60: 773, 1985.
9. Nestler J.E., Jacubowicz D.J. Decreases in ovarian cytochrome P450 c17α activity and serum free testosterone after reduction of insulin secretion in PCOS. N. Engl. J. Med. 335: 617, 1996.
10. Dunaif A., Scott D., Finegood D., Quintana B., Whitcomb R. The insulin sensitizing agent Troglitazone improves metabolic and reproductive abnormalities in PCOS. J. Clin. Endocrinol. Metab. 81: 3299, 1996.
11. Acbay O., Gundogdu S. Can metformin reduce insulin resistance in PCOS. Fertil. Steril. 65: 946, 1996.
12. Barnes R.B., Rosenfield R.L., Ehrman D.A., Cara J.F., Cuttler L., Levitsky L.L., Rosenthal I.M. Ovarian hyperandrogenism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J. Clin. Endocrinol. Metab. 79: 1328, 1994.
13. Dunaif A. Do androgens directly regulate gonadotropin secretion in the polycystic ovary syndrome? J. Clin. Endocrinol. Metab. 63: 215, 1986.
14. Apter D., Butzow T., Laughlin G.A., Yen S.S.C. Accelerated 24h. LH pulsatile activity in adolescent girls with ovarian hyperandrogenism - relevance to the developmental phase of PCOS. J. Clin. Endocrinol. Metab. 79: 119, 1994.
15. Apter D., Vihko R. Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J. Clin. Endocrinol. Metab. 71: 970, 1990.
16. Dalkin A.C., Haisenleder D.J., Ortolano G.A., Ellis T., Marshall J.C. The frequency of gonadotropin-releasing hormone (GnRH) stimulation differentially regulates gonadotropin subunit mRNA expression. Endocrinology 125: 917, 1989.
17. Daniels T.L., Berga S.L. Resistance of gonadotropin releasing hormone drive to sex-steroid induced suppression in hyperandrogenic anovulation. J. Clin. Endocrinol. Metab. 82: 4179, 1997.
18. Pastor C.L., Griffin-Korf M.L., Aloi J.A., Evans W.S., Marshall J.C. Polycystic ovary syndrome: evidence for reduced sensitivity of the GnRH pulse generator to inhibition by estradiol and progesterone. J. Clin. Endocrinol. Metab. 83: 582, 1998.
19. Apter D. Serum steroids and pituitary hormones in female puberty: a partly longititudinal study. Clin. Endocrinol. (Oxf.) 12: 107, 1980.
20. Marshall J.C., Kelch R.P. Gonadotropin-releasing hormone - Role of pulsatile secretion in the regulation of reproduction. N. Engl. J. Med. 315: 1459, 1986.
21. Soules M.R., Steiner R.A., Clifton D.K., Cohen N.L., Aksel S., Bremner W.J. Progesterone modulation of pulsatile luteinizing hormone in normal women. J. Clin. Endocrinol. Metab. 58: 378, 1984.
22. Pang S. Relevance of biological properties of progestogen of oral contraceptives in treatment of androgen excess symptoms. J. Clin. Endocrinol. Metab. 71: 5, 1990.
23. Rittmaster R.S. Medical treatment of androgen-dependent hirsutism. J. Clin. Endocrinol. Metab. 80: 2559, 1995.
24. Golland I.M., Elstein M.E. Results of an open one year study with Diane-35 in women with polycystic ovarian syndrome. Ann. NY Acad. Sci. 687: 263, 1993.
25. Cusan L., Dupont A., Gomez J.-L., Tremblay R., Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril, 61: 281, 1994.
26. Erenus M., Gurbuz O., Dumusoglu F., Demircay Z., Pekin S. Comparison of the efficacy of spironolactone vs flutamide in the treatment of hirsutism. Fertil. Steril. 61: 613, 1994.
27. DeLeo V., Lanzetta D., D'antona D., La Marca A., Margante G. Hormonal effects of flutamide in young women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 83: 99, 1998.
28. De Zeigler D., Steingold K., Cedars M., Lu J.K.H., Meldrum D.R., Judd H.L., Chang R.J. Recovery of hormone secretion after chronic GnRH-against administration in women with polycystic ovarian disease. J. Clin. Endocrinol. Metab. 68: 1111, 1989.
29. Christman G.M., Randolph J.F., Kelch R.P., Marshall J.C. Reduction of gonadotropin-releasing hormone pulse frequency is associated with subsequent selective follicle-stimulating hormone secretion in women with polycystic ovarian syndrome. J. Clin. Endocrinol. Metab. 72: 1278, 1991.
30. Evans J.H., Taft H.R., Brown J.B., Adey F.D., Johnstone J.W. Induction of ovulation by cyclical hormone therapy. J. Obstet. Gynec. Brit Commwlth 74: 367, 1967.
31. Stuckey B.G.A., Keogh E.J., Pullan P.T., Beilby J.A., Thompson R.I., Evans D.V. Continuous gonadotropin-releasing hormone for ovulation induction in polycystic ovarian disease. Fertil. Steril. 48: 1055, 1987.